Healthcare / Drug Manufacturers - Specialty & GenericNasdaqCM
$3.64
+0.04 (+1.11%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-85.3M · quality 57.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
43/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$215M
P/E
91.0x
↑EV/EBITDA
3.2x
↓ROE
0.3%
↑Gross Margin
54.6%
↑Debt/Equity
0.18
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
+8.8%
FCF CAGR
—
FCF margin
-0.8%
FCF / Net income
-1.79x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $343.3M · net income $1.6M · FCF $-2.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $343.3M | $343.3M | $269.6M | $221.3M | $245.3M |
| Net Income | $1.6M | $1.6M | $-69.3M | $-1.72B | $-693.6M |
| EBITDA | $51.3M | $51.3M | $-11.1M | $-1.55B | $-535.3M |
| EPS | 0.04 | 0.04 | -1.52 | -79.90 | -41.00 |
| Gross Margin | 54.6% | 54.6% | 48.9% | 9.6% | -8.8% |
| Operating Margin | 2.9% | 2.9% | -11.5% | -99.1% | -100.6% |
| Net Margin | 0.5% | 0.5% | -25.7% | -776.0% | -282.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.18 | 0.18 | 0.19 | 0.41 | 0.20 |
| Current Ratio | 3.06 | 3.06 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.9M | $-2.9M | $-85.3M | $-142.5M | $-263.7M |
| Returns | |||||
| ROE | 0.3% | 0.3% | -12.4% | -259.5% | -34.0% |
| Valuation | |||||
| P/E | 91.00 | 91.00 | — | — | — |
| EV/EBITDA | 3.24 | 3.24 | — | — | — |
| P/B | 0.35 | 0.35 | 0.51 | 0.44 | 0.72 |
| Growth & Yield | |||||
| Revenue Growth | 27.3% | 27.3% | 21.8% | -9.8% | — |
| EPS Growth | 102.6% | 102.6% | 98.1% | -94.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
100.6%
EPS terminal req.
$0.32
Spread vs growth
2.0%
5Y implied EPS CAGR
57.8%
EPS terminal req.
$0.39
Spread vs growth
44.9%
10Y implied EPS CAGR
31.7%
EPS terminal req.
$0.63
Spread vs growth
70.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-31.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.52 → 0.04
Residual
-31.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.